Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report
- PMID: 33089050
- PMCID: PMC7454487
- DOI: 10.1093/ehjcr/ytaa218
Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report
Abstract
Background: Early studies have led to the repositioning of a subgroup of antimalarial agents (e.g. chloroquine and hydroxychloroquine) as antiviral treatment in coronavirus disease 2019 (COVID-19) patients. These drugs are now being prescribed based on small non-controlled studies, but larger controlled studies have yet to demonstrate the positive effect of these drugs. In addition, these drugs are also known for their QT interval-prolonging effect associated with significant morbidity and mortality.
Case summary: We present a case of a 66-year-old female admitted to the intensive care unit with respiratory failure due to COVID-19. She was treated with chloroquine (QTc interval at baseline was 429 ms). Despite cessation of chloroquine, but after the start of erythromycin, she developed severe QTc interval prolongation (QTc interval 550 ms) and 'Torsade de Pointes'. Two weeks after cessation of all QTc interval-prolonging drugs, the QTc interval was restored.
Discussion: The elimination half-life of chloroquine ranges from days up to weeks. Even after discontinuation of chloroquine, ECG monitoring in COVID-19 patients is warranted. We recommend observation of the QT interval after cessation of chloroquine in cases where other potentially QT interval-prolonging drugs are introduced.
Keywords: COVID-19; Case report; Chloroquine; Coronavirus; QT interval prolongation; SARS-CoV-2; Torsade de Pointes.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
Figures
Similar articles
-
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29. Circ Arrhythm Electrophysiol. 2020. PMID: 32347743 Free PMC article.
-
Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?Drug Alcohol Rev. 2011 Jul;30(4):388-96. doi: 10.1111/j.1465-3362.2010.00237.x. Epub 2010 Sep 6. Drug Alcohol Rev. 2011. PMID: 21355918
-
Chloroquine-induced QTc prolongation in COVID-19 patients.Neth Heart J. 2020 Jul;28(7-8):406-409. doi: 10.1007/s12471-020-01429-7. Neth Heart J. 2020. PMID: 32350818 Free PMC article.
-
Perioperative torsade de pointes: a systematic review of published case reports.Anesth Analg. 2013 Sep;117(3):559-564. doi: 10.1213/ANE.0b013e318290c380. Epub 2013 Jun 6. Anesth Analg. 2013. PMID: 23744954 Free PMC article. Review.
-
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22. Z Gerontol Geriatr. 2018. PMID: 27878411 Review. English.
Cited by
-
Prolonged Exposure to Remdesivir Inhibits the Human Ether-A-Go-Go-Related Gene Potassium Current.J Cardiovasc Pharmacol. 2023 Sep 1;82(3):212-220. doi: 10.1097/FJC.0000000000001449. J Cardiovasc Pharmacol. 2023. PMID: 37410999
-
Safety profile of COVID-19 drugs in a real clinical setting.Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28. Eur J Clin Pharmacol. 2022. PMID: 35088108 Free PMC article. Review.
-
Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.Toxicol Sci. 2021 Apr 12;180(2):356-368. doi: 10.1093/toxsci/kfaa194. Toxicol Sci. 2021. PMID: 33483756 Free PMC article.
References
-
- Gao J, Tian Z, Yang X.. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–73. - PubMed
-
- Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO Jr, Naveca FG, Xavier MS, Siqueira AM,, Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ, Albuquerque BC, Daniel-Ribeiro CT, Monteiro WM,, Lacerda MVG; CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020;3:e208857. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous